Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 9, 2007, Pages 927-936

  Vicuna, Brian ^a   Benson III, Al B ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Clinical trials; Colon cancer; Molecular markers; Stage II; Treatment

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; VINCRISTINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; GENE EXPRESSION; HUMAN; MONOTHERAPY; PATHOGENESIS; REVIEW;

EID: 35948984483     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0080     Document Type: Review

References (56)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57:43-66.
2. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999-4005.
3. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective [abstract]. Semin Oncol 2001;28(1 Suppl 1):20-24.
4. Dukes C. The classification of cancer of the rectum. J Pathol Bact 1932:323-332.
5. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-852.
6. Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318-324.
7. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425.
8. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol 2003;21:2912-2919.
9. Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002;235:458-463.
10. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99:433-441.
11. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-596.
12. Burdy G, Panis Y, Alves A, et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-1688.
13. Morris M, Platell C, de Boer B, et al. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006;93:866-871.
14. Petersen VC, Baxter KJ, Love SB, Sherpherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:65-69.
15. Morris E, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant thetapy in Dukes B/stage II colorectal cancer? - The need for high quality pathology. Gut 2007;56:1419-1425.
16. Soreide K, Janssen EA, Soiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg 2006;93:395-406.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
18. Gafa R, Maestri I, Matteuzzi M, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000;89:2025-2037.
19. Ward R, Maegher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001;48:821-829.
20. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257.
21. Lanza G, Gafa R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006;24:2359-2367.
22. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767-772.
23. Popat S, Hubnet R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
24. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.
25. Funaioli C, Pinto C, Mutri V, et al. Does biomolecular characterization of stage II/III colorectal cancet have any prognostic value? Clin Colorectal Cancer 2006;6:38-45.
26. Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004;22:1572-1582.
27. Sinicrope FA, Rego RL, Hailing KC, et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 2006;12:2738-2744.
28. Resnick MB, Routhier J, Konkin T, et al. Epidetmal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004;10:3069-3075.
29. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-1571.
30. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685-4691.
31. Bandres E, Malumbres R, Cubedo E, et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep 2007;17:1089-1094.
32. Barrier A, Roser F, Boelle PY, et al. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 2007;26:2642-2648.
33. Johnston PG, Mulligan K, Kay E, et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array [abstract]. J Clin Oncol 2006;24(Suppl 1):150s. Abstract 3519.
34. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30-36.
35. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer [abstract]. Semin Oncol 2001;28(1 Suppl 1):9-13.
36. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;22:352-358.
37. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-2943.
38. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
39. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23:8671-8678.
40. Gray R, Barnwell J, Hills R. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients [abstract]. J Clin Oncol 2004;22(Suppl 14):246s. Abstract 3501.
41. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355.
42. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. Inrernational Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17:1356-1363.
43. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
44. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395-3407.
45. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
46. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
47. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
48. Van Cutsem E, Labianca R, Hossfeld D. Randomized phase III trial comparing infused irinotecan/5-flurorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA(F) in stage III colon cancer patients PETACC3. [abstract]. J Clin Oncol 2005;23(Suppl 1):3s. Abstract LBA8.
49. Ychou M, Raoul JL, Douillatd JY, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) [abstract]. J Clin Oncol 2005;23(Suppl 1):246s. Abstract 3502.
50. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-3461.
51. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-2204.
52. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
53. Hickish T, Boni C, Navarro M. FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial [abstract]. J Clin Oncol 2004;22(Suppl 1): Abstract 3619.
54. de Gramont A, Boni C, Navarro M. Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the Mosaic trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol 2007;25(Suppl 1):165s. Abstract 4007.
55. O'Connell MJ. Survival following recurrence in patients with adjuvant colon cancet: findings from the 20,800 patient ACCENT dataset [abstract]. J Clin Oncol 2007;25(Suppl 1):165s. Abstract 4009.
56. Sargent DJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient (pt) ACCENT dataset [abstract]. J Clin Oncol 2007;25(Suppl 1):165s. Abstract 4008.